Legend Biotech Results Presentation Deck

8 CARVYKTIⓇ Uptake Continues Continued market penetration, population in earlier lines of treatment represents significant opportunity for continued growth 160 140 120 100 80 60 40 20 0 CARVYKTIⓇ Net Product Sales ($MM) U.S. 0 24 55 EU O 55 +176% growth vs Q3'22 70 3 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 114 12 140 Q3 2023 This presentation is for investor relations purposes only - Not for product promotional purposes U.S. ● EU Global YOY Growth 155% N/A 176% QoQ Growth 23% 300% 30% → U.S. QoQ growth of 23% primarily driven by: Ongoing launch Market share expansion Capacity improvements Number of activated U.S. treatment sites increased to 60 EU QOQ growth of 300% primarily due to ongoing launch in Germany LEGEND BIOTECH

View entire presentation